Recombinantly Modified Plasmin
AssigneeTalecris Biotherapeutics, Inc.
InventorsJennifer A. Hunt, Valery Novokhatny
Life of this patent
Estimating the term…
Abstract
Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.
Claims21
A polynucleotide comprising a nucleotide sequence encoding a polypeptide having a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen;
- and a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen;
- wherein the polypeptide binds to immobilized lysine.
A polypeptide comprising a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen;
- and a C-terminal domain activation site and serine protease domain homologous to the corresponding domains in human plasminogen, wherein the polypeptide binds to immobilized lysine.
A polypeptide comprising a single kringle domain located N-terminal to a plasminogen activation site and plasminogen serine protease domain, wherein the kringle domain has at least one residue greater amino acid sequence identity with kringle 1 or kringle 4 of native human plasminogen than with kringle 5 of native human plasminogen, and wherein conservative substitutions of the single kringle region relative to the native sequences of kringles 1 and 4 of human plasminogen are not considered as differing from the native sequences for purposes of the identity comparison with kringle 5.
Dependencies are inferred from the claim text.